Potassium Carbonate → HCID 67365468, compound
Reaction equation
C([O:4][CH2:5][C:6]([N:8]1[CH2:12][CH2:11][C@@H:10]([C:13]2[N:17]3[CH:18]=[CH:19][N:20]=[C:21]([CH3:22])[C:16]3=[C:15]([Br:23])[N:14]=2)[CH2:9]1)=[O:7])(=O)C.C(=O)([O-])[O-].[K+].[K+]>CO>[Br:23][C:15]1[N:14]=[C:13]([C@@H:10]2[CH2:11][CH2:12][N:8]([C:6](=[O:7])[CH2:5][OH:4])[CH2:9]2)[N:17]2[CH:18]=[CH:19][N:20]=[C:21]([CH3:22])[C:16]=12Participants
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
To (R)-2-(3-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)pyrrolidin-1-yl)-2-oxoethyl acetate (0.105 mmol, 40 mg) in methanol (4 ml) was added potassium carbonate (0.126 mmol, 17.40 mg). After stirring the reaction mixture at room temperature for one hour, the solids were removed by filtration and the filtrate concentrated in vacuo to give (R)-1-(3-(1-bromo-8-methylimidazo[1,5-a]pyrazin-3-yl)pyrrolidin-1-yl)-2-hydroxyethanone (35.6 mg). Reaction of the latter compound (35.6 mg) and 4-methoxy-N-(2-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1-methyl-1H-indole-2-carboxamide (50 mg) according to the procedure described in example 4 step 4c and purification using prep-HPLC (column Luna C18(2); gradient acetonitrile/water with constant 0.003M trifluoroacetic acid) gave ((R)—N-(4-(3-(1-(2-hydroxyacetyl)pyrrolidin-3-yl)-8-methylimidazo[1,5-a]pyrazin-1-yl)-2-methoxyphenyl)-4-methoxy-1-methyl-1H-indole-2-carboxamide (25.8 mg).
Workup
- customthe solids were removed by filtration
- concentrationthe filtrate concentrated in vacuo
Sources & evidence
- ORD record
- ord-35df8d1bc7c349fe96403459eaba477e
- Source dataset
- uspto-grants-2014_02
- Patent number
- US08658794B2
Reaction notes
Loading…